1639924-58-5

Basic information

• Product Name: (2S,5R)-2,5-diMethylMorpholine
• Synonyms: (2S,5R)-2,5-diMethylMorpholine;(2S,5R)-2,5-dimethylmorpholin
• CAS NO: 1639924-58-5
• Molecular Formula: C6H13NO
• Molecular Weight: 115.17352
• Mol File: 1639924-58-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 150.8±15.0 °C(Predicted)
• Appearance: /
• Density: 0.862±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.07±0.60(Predicted)
• CAS DataBase Reference: (2S,5R)-2,5-diMethylMorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5R)-2,5-diMethylMorpholine(1639924-58-5)
• EPA Substance Registry System: (2S,5R)-2,5-diMethylMorpholine(1639924-58-5)

Safety Data

• Hazardous Substances Data: 1639924-58-5(Hazardous Substances Data)

Usage

Uses

(2S,5R)-2,5-Dimethylmorpholine is a variation of Morpholine (M723725) which is used as selective inhibitors of cytochrome p450 2a13 in treatment of cancer. Morpholine is a building block in the preparation of the antibiotic Linezolid (L466500), the anticancer agent Gefitinib (G304000) and the analgetic Dextromoramide (M630190).

Upstream product

• 115893-42-0 (β-hydroxy-isopropyl)-(2-hydroxy-propyl)-amine 
• 106-62-7 Dipropylene glycol 
• 1235469-35-8 (2R,5R)-benzyl 2,5-dimethylmorpholine-4-carboxylate 
• 115206-98-9 (2S,5S)-2,5-Dimethyl-3-oxoperhydro-1,4-oxazin 
• 115206-95-6 (1'S,2S)-2-Chlor-N-(2'-hydroxy-1'-methylethyl)propionsaeureamid 
• 115206-95-6 (R)-2-Chloro-N-((S)-2-hydroxy-1-methyl-ethyl)-propionamide 
• 1235469-32-5 (2R,5S)-2,5-dimethyl-4-tosylmorpholine 
• 110-97-4 diisopropanolamine 

Downstream Products

• 1605317-40-5 (2R,5S)-5-((2R,5R)-2,5-dimethyl-morpholin-4-ylmethyl)-4-{2-[6-(4-fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-oxo-ethyl}-2-methyl-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Preparation method of high-purity cis-2,6-dimethylmorpholine

The invention relates to the technical field of chemical synthesis of medicines, and discloses a preparation method of high-purity cis-2,6-dimethylmorpholine. The method comprises the following steps:subjecting a cis-2,6-dimethylmorpholine-rich mixture of cis-2,6-dimethylmorpholine, trans-2, 6-dimethylmorpholine, cis-2,5-dimethylmorpholine and trans-2,5-dimethylmorpholine to salt formation with micromolecular aliphatic carboxylic acid in an ester solvent, and carrying out recrystallizing to obtain cis-2,6-dimethylmorpholine carboxylate; and dissociating the cis-2,6-dimethylmorpholine carboxylate by using a strong alkaline substance to obtain the high-purity cis-2,6-dimethylmorpholine. According to the method disclosed by the invention, environment-friendly ethyl acetate, isopropyl acetateand butyl acetate are used as reaction solvents and also used as recrystallization solvents, so realization of green production is facilitated which reduction of pollution is realized, impurity content is effectively controlled, finished product purity reaches 99.9% or above, used acids and solvents are friendly to environment, and the method is suitable for industrial production.

Steric effects in the catalytic amination of γ-, δ-, and ε-glycols

The amination of butane-1,4-diol, isomeric dipropylene glycols, and cyclohexane-1,4-diyldimethanol in the presence of nickel/copper/chromium catalysts has been studied. The effect of the initial glycol structure on the reaction selectivity has been estima

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.